JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB287185

Human ACKR3 knockout HCT116 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

ACKR3 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.

View Alternative Names

RDC1, Chemokine orphan receptor 1, CMKOR1, C-X-C chemokine receptor type 7, G-protein coupled receptor 159, Atypical chemokine receptor 3, ACKR3, G-protein coupled receptor RDC1 homolog, CXCR7, CXCR-7, GPR159, RDC-1, CXC-R7

1 Images
Next Generation Sequencing - Human ACKR3 knockout HCT116 cell line (AB287185)
  • NGS

Lab

Next Generation Sequencing - Human ACKR3 knockout HCT116 cell line (AB287185)

94 bp deletion in exon 1, CCDS2516.1

Key facts

Cell type

HCT116

Species or organism

Human

Tissue

Colon

Form

Liquid

form

Knockout validation

Next Generation Sequencing

Disease

Carcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "NGS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Properties and storage information

Gene name
ACKR3
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

GPCR RDC1 also known as CXCR-7 is a G protein-coupled receptor that binds to chemokines such as CXCL12 and CXCL11. The receptor has a predicted molecular mass of approximately 40 kDa. It expresses widely in various tissues with high levels found in the heart liver kidney and brain. This receptor plays a role in the trafficking and localization of different cells often working alongside or complementing other chemokine receptors.
Biological function summary

GPCR RDC1/CXCR-7 takes part in complex cell signaling related to cell growth survival and migration. It is not usually part of a classic GPCR signaling pathway which sets it apart from other receptors in its family. Instead it can modulate pathways by forming heterodimers with other receptors such as CXCR4 affecting both ligand availability and receptor sensitivity. CXCR-7 can also function as a decoy receptor binding ligands without initiating a typical signaling cascade.

Pathways

The participation of GPCR RDC1/CXCR-7 is noted in chemokine-mediated pathways. Of particular importance is the SDF-1/CXCL12 signaling pathway which it shares with CXCR4. This pathway plays an important role in the regulation of stem cell migration and homing. CXCR-7 modulates the bioavailability of CXCL12 and influences how CXCR4 triggers downstream effects affecting cellular response to the external environment.

GPCR RDC1/CXCR-7 holds significance in cancer and cardiovascular diseases. In cancer overexpression of CXCR-7 associates with tumor growth and metastasis often in conjunction with the action of CXCR4. In cardiovascular conditions altered expression and functional shifts in CXCR-7 can lead to abnormal vascularization contributing to disease progression. Its role in these diseases makes CXCR-7 a valuable target for therapeutic interventions.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability. <p>1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.<br>2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.<br>3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.<br>4. Incubate the culture at 37°C incubator with 5% CO<sub>2</sub>. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.<br>5. Once confluent passage into an appropriate flask at a density of 2x10<sup>4</sup> cells/cm<sup>2</sup>. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.</p>

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

McCoY5a + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com